Article

The current management of pancreatic neuroendocrine tumors.

Department of Surgery, The Johns Hopkins Hospital, 1550 Orleans Street, CRB II, Room 506, Baltimore, MD 21287, USA.
Advances in Surgery 09/2012; 46:283-96. DOI: 10.1016/j.yasu.2012.04.002
Source: PubMed

ABSTRACT PanNETs constitute a rare and heterogeneous group of pancreatic neoplasms whose overall prognosis is better than the more common pancreatic adenocarcinoma. Although surgery is the only treatment that provides a cure, many adjuvant therapies have been explored with some new, exciting, targeted therapies just approved for PanNETs. With growing interest in this type of neoplasm, an increasing number of clinical trials and natural history studies should shed light on the best management for these patients.

0 Bookmarks
 · 
124 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic neuroendocrine tumors (PNET) are rare, often indolent malignancies. PNET are classified as functional or nonfunctional based on the secretion of hormones without a negative feedback loop; the latter account for up to 60% of PNET. Although PNET are associated with a better prognosis compared to pancreatic adenocarcinomas, they are often diagnosed in advanced stages, making them a significant source of morbidity for patients. Here we present a rare case of venous tumor thrombus arising from a nonfunctional PNET.
    11/2014; 5(12). DOI:10.1016/j.ijscr.2014.11.045
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present a case of newly diagnosed lung adenocarcinoma and a five-month history of diarrhea. The patient was found to have elevated chromogranin A serum levels and the tumor displayed histologic and immunohistochemical features of neuroendocrine differentiation. Upon lobectomy and tumor resection, the chromogranin A levels normalized and the diarrhea resolved completely. This is the first reported case of paraneoplastic diarrhea associated with lung adenocarcinoma.
    Clinical Journal of Gastroenterology 10/2013; 6(5). DOI:10.1007/s12328-013-0407-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic vipoma is an extremely rare tumor accounting for less than 2% of endocrine pancreatic neoplasms with a reported incidence of 0.1-0.6 per million. While cross-sectional imaging findings are usually not specific, exact localization of the tumor by means of either computed tomography (CT) or magnetic resonance (MR) is pivotal for surgical planning. However, cross-sectional imaging findings are usually not specific and further characterization of the tumor may only be achieved by somatostatin-receptor scintigraphy (SRS). We report the case of a 70 years old female with a two years history of watery diarrhoea who was found to have a solid, inhomogeneously enhancing lesion at the level of the pancreatic tail at Gadolinium-enhanced MR (Somatom Trio 3T, Siemens, Germany). The tumor had been prospectively overlooked at a contrast-enhanced multi-detector CT (Aquilion 64, Toshiba, Japan) performed after i.v. bolus injection of only 100 cc of iodinated non ionic contrast media because of a chronic renal failure (3.4 mg/mL) but it was subsequently confirmed by SRS. The patient first underwent a successful symptomatic treatment with somatostatin analogues and was then submitted to a distal pancreasectomy with splenectomy to remove a capsulated whitish tumor which turned out to be a well-differentiated vipoma at histological and immuno-histochemical analysis.